Gilead Sciences
GILD
$146.41
+1.87%
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes therapies for life-threatening infectious diseases, with its core franchise anchored in HIV and hepatitis B and C treatments, complemented by a growing oncology portfolio built around CAR-T cell therapies Yescarta and Tecartus and the antibody-drug conjugate Trodelvy. As one of the largest pure-play antiviral franchises in global pharma, Gilead holds a dominant, near-franchise-like position in HIV, where its regimens remain standards of care, while it positions itself as an emerging challenger in oncology and inflammation through serial bolt-on and mid-cap acquisitions. The current investor narrative centers on whether the company can convert its cash-generative HIV base into a durable second growth engine: the recent Bixlenvo approval and raised 2026 HIV sales guidance have reinvigorated the bull case, even as the termination of the Trodelvy-Keytruda lung cancer trial and a string of multi-billion-dollar deals (Arcellx at $7.8 billion, Tubulis at $3.15 billion, Ouro Medicines) underscore the pipeline risk and capital-allocation debate. Sentiment is further shaped by a 100% drug tariff regime that exempts Gilead as one of the signatory companies, a structural competitive advantage, and by a stock that has recovered strongly off its spring lows but remains range-bound versus its 52-week high.…
GILD
Gilead Sciences
$146.41
Related headlines
Investment Opinion: Should I buy GILD Today?
Gilead Sciences is rated a Buy based on a synthesis of its deep value valuation, strong cash generation, and the potential for HIV reacceleration from Bixlenvo. The analyst consensus rating of 1.75 (buy) and average target price of $158.15 imply roughly 10% upside, which, combined with a 2.62% dividend yield, offers a total return potential of about 12-13% over the next year. The core thesis is that Gilead's discounted forward PE of 14.53x and 6.7% free cash flow yield provide a margin of safety, while the Bixlenvo launch and tariff exemption offer catalysts for multiple expansion.
Supporting evidence includes the company's robust profitability, with a 79.24% gross margin, 29.04% net margin, and 39.74% operating margin, all well above large-cap pharma averages. Revenue growth of 4.39% YoY is modest but stable, and the HIV franchise generates $5.03 billion in quarterly revenue, providing a cash cow to fund oncology expansion. The balance sheet is healthy with a current ratio of 1.553 and ROE of 37.49%, and the 47.04% payout ratio leaves room for dividend growth. The stock's low beta of 0.35 makes it a defensive holding, and its relative strength versus SPY has been positive over 1, 3, and 12 months.
The biggest risks that could invalidate the thesis are: (1) failure of Bixlenvo to drive HIV growth, (2) further oncology pipeline setbacks like the Trodelvy-Keytruda trial termination, and (3) margin compression from acquisition amortization. The rating would upgrade to a Strong Buy if revenue growth accelerates above 6% and the forward PE remains below 15x, or downgrade to Hold if HIV sales decline or the oncology pipeline suffers another major failure. Relative to its historical PE band of 10.71x to 26.43x, the current 17.94x trailing PE is near the middle, suggesting the stock is fairly valued with a slight discount to peers. The valuation verdict is fairly valued to slightly undervalued, with the potential for multiple expansion if growth reaccelerates.
Sign up to view all
GILD 12-Month Price Forecast
Gilead presents a balanced risk/reward profile, with the stock trading at a discount to peers but facing modest growth prospects. The Bixlenvo approval and raised HIV guidance are positive catalysts, but the Trodelvy trial failure and aggressive M&A strategy introduce uncertainty. The low beta of 0.35 makes it a defensive holding, but the upside is limited without a clear growth inflection. I would upgrade to bullish if HIV growth accelerates above 6% and the oncology pipeline delivers positive data, or downgrade to bearish if HIV sales decline or another major trial fails. The base case of $150-165 appears most likely, supported by the analyst average target of $158.15.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $158.15 and implied upside of +8.0% versus the current price.
Average Target
$158.15
0 analysts
Implied Upside
+8.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$123 - $180
Analyst target range
Coverage is broad and constructive, with 27 analysts following Gilead and a consensus recommendation of "buy" (recommendation mean of 1.75 on a 1-5 scale where 1 is strong buy). The average target price is $158.15, which against the current price of $143.72 implies roughly +10.0% upside, and the consensus EPS estimate of $13.09 (range $12.65-$13.64) on estimated revenue of $39.00 billion (range $38.01-$40.28 billion) underpins that target. The sentiment leans bullish but not aggressively so: the 1.75 mean sits between a strong buy and a buy, and the modest 10% implied upside suggests analysts see the stock as fairly valued with room for modest appreciation rather than deeply undervalued. The target range is wide, from a low of $123.00 to a high of $180.00, a spread of $57.00 or about 40% of the current price, which signals meaningful disagreement about the pipeline and growth trajectory. The high target of $180.00 implies roughly +25% upside and would require multiple expansion toward 18-20x forward earnings plus successful execution on the Arcellx myeloma program and Bixlenvo-driven HIV reacceleration, while the low target of $123.00 implies about -14% downside and prices in margin compression from acquisition amortization, continued Trodelvy disappointment, and flat HIV growth. Institutional ratings show a clear pattern of upgrades and reiterations rather than downgrades: HSBC moved from Hold to Buy on 2026-07-06, Maxim Group moved from Hold to Buy on 2026-05-20, and Morgan Stanley, Truist, Cantor Fitzgerald, and Citigroup all reiterated bullish or constructive ratings through mid-2026, with RBC Capital the notable neutral at Sector Perform. The combination of a tight consensus around a buy rating, a wide target spread, and a recent stream of upgrades suggests positive but not euphoric sentiment, with the stock's low beta of 0.35 making it a defensive holding whose upside case depends on pipeline catalysts rather than multiple re-rating alone.
Drowning in data?
Find the real signal!
Bulls vs Bears: GILD Investment Factors
The bull case currently has stronger evidence, driven by Gilead's deep value valuation (14.53x forward PE, 6.7% FCF yield), the Bixlenvo-driven HIV reacceleration, and a tariff exemption that creates a competitive moat. However, the bear case is not without merit: revenue growth remains stuck at 4.39%, the Trodelvy lung cancer trial failure underscores pipeline risk, and the aggressive M&A strategy adds integration risk. The single most important tension is whether Bixlenvo can sustainably reaccelerate HIV growth toward mid-single digits, which would justify multiple expansion and a move toward the analyst high target of $180. If HIV growth remains flat and oncology disappoints, the stock could remain range-bound or drift toward the low target of $123. Overall, the risk/reward skews positive given the low beta, strong cash generation, and discounted valuation, but the upside is capped without a clear growth inflection.
Bullish
- Bixlenvo approval reaccelerates HIV franchise: The recent Bixlenvo approval and raised 2026 HIV sales guidance directly address the biggest bear concern: that Gilead's core HIV business is maturing. HIV products already generate $5.03 billion in quarterly revenue, and a successful Bixlenvo launch could push overall growth from the current 4.39% YoY toward mid-single digits, providing the catalyst for multiple expansion.
- Deep value valuation with 6.7% FCF yield: Gilead trades at a forward PE of 14.53x and EV/EBITDA of 12.52x, both well below the 15-18x range typical for large-cap pharma peers. With TTM free cash flow of $10.23 billion against a $152.7 billion market cap, the FCF yield of 6.7% offers a compelling cash return that supports both the 2.62% dividend yield and continued buybacks.
- Tariff exemption creates competitive moat: The 100% drug tariff regime exempts Gilead as one of the signatory companies, while posing a severe threat to holdouts. This structural advantage could allow Gilead to gain market share and pricing power relative to competitors who face higher import costs, enhancing its already strong 79.24% gross margin.
- Analyst consensus buy with 10% upside: 27 analysts rate Gilead a 'buy' with a mean recommendation of 1.75 and an average target price of $158.15, implying roughly 10% upside from the current $143.72. Recent upgrades from HSBC and Maxim Group, plus reiterations from Morgan Stanley and Citigroup, suggest positive sentiment momentum.
Bearish
- Revenue growth stuck in low single digits: Q1 2026 revenue grew only 4.39% YoY to $6.96 billion, and the trailing four quarters show a flat-to-slightly-up pattern with no clear inflection. This modest growth rate justifies the discounted valuation but limits upside unless Bixlenvo and oncology assets can meaningfully accelerate the top line.
- Oncology pipeline suffers major setback: The termination of the Trodelvy-Keytruda lung cancer trial in June 2026 highlights the high-risk nature of Gilead's oncology pivot. Trodelvy contributed only $402 million in quarterly revenue, and this failure raises questions about the company's ability to build a durable second growth engine beyond HIV.
- Aggressive M&A strains balance sheet: Gilead has spent billions on acquisitions (Arcellx at $7.8 billion, Tubulis at $3.15 billion, Ouro Medicines), driving debt-to-equity to 1.098. These deals will add amortization and integration costs that could pressure reported margins, even as they build the long-term pipeline.
- HIV concentration risk remains extreme: HIV products account for $5.03 billion of the $6.96 billion quarterly revenue, or over 72% of total sales. Any pricing pressure, competitive threat, or regulatory change in the HIV market would have an outsized impact on Gilead's financials, as the oncology portfolio is still sub-scale.
GILD Technical Analysis
Gilead is in a recovery uptrend that has stalled near the top of its range. The stock is up 21.94% over the past year and 18.19% year-to-date, but the 6-month change of -0.88% reveals that essentially all of the gain was earned in the last three months, with the current price of $143.72 sitting at roughly 72% of the 52-week range between a low of $108.46 and a high of $157.29. That positioning means the stock has reclaimed most of its drawdown (max drawdown -22.03%) but is not yet at breakout territory, leaving it in the upper-middle of a wide consolidation band rather than at a momentum extreme. Momentum has been constructive but is now cooling. The 1-month change of +5.78% and 3-month change of +14.44% confirm a strong spring-to-summer advance, yet the most recent sessions show a pullback from the September 3 high of $151.22 to $143.72, a decline of about 5.0% in six trading days, and the prior day's -0.75% close suggests near-term selling pressure. Relative strength versus SPY is decisively positive over 1 month (+6.84 points), 3 months (+11.40 points), and 1 year (+5.72 points), but the 6-month relative strength of -16.28 points shows Gilead lagged badly during the spring, so the current move is best read as a catch-up rally that is now testing whether buyers will defend the breakout. Key levels are well defined: resistance sits at the 52-week high of $157.29, roughly 9.4% above the current price, and a decisive close above that level would confirm a new leg higher and likely draw momentum capital; support lies at the 52-week low of $108.46, about 24.5% below, with intermediate support around the $130-$135 zone where the stock consolidated in July and August. The beta of 0.35 is the critical risk-management input: Gilead moves at roughly one-third the volatility of the S&P 500, so position sizing can be larger for a given dollar risk, but the low beta also means the stock will not deliver explosive upside in a broad market melt-up and is better suited to defensive, income-oriented portfolios.
Beta
0.35
0.35x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+27.8%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | -2.0% |
| 3m | +15.1% | +1.4% |
| 6m | +3.6% | +15.0% |
| 1y | +27.8% | +15.7% |
| ytd | +20.4% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Revenue is growing but at a modest, steady pace rather than accelerating. The most recent quarter (Q1 2026, ended 2026-03-31) delivered revenue of $6.96 billion, up 4.39% year-over-year, with gross profit of $5.515 billion; the trailing four quarters show revenue of $6.96 billion, $7.924 billion, $7.769 billion, and $7.081 billion, a pattern that is essentially flat-to-slightly-up with no clear inflection. Segment data shows the concentration risk and the growth engine: total other HIV products contributed $5.03 billion, cell therapy products $482 million, Trodelvy $402 million, Veklury $144 million, and other products $196 million, meaning HIV remains the overwhelming majority of the franchise while oncology assets are still sub-scale. The implication for the investment case is that Gilead is a cash-cow compounder dependent on HIV pricing and volume, and the raised 2026 HIV guidance tied to Bixlenvo is the single most important swing factor for whether the 4.4% growth rate can reaccelerate toward mid-single digits. Profitability is robust and improving. Q1 2026 net income was $2.021 billion on a 29.04% net margin, with a gross margin of 79.24% and an operating margin of 39.74%, and the quarterly progression shows net margin expanding from 27.55% in Q4 2025 and 27.68% in Q2 2025 to 29.04% in the latest quarter, while gross margin has held in a tight 78.8%-79.8% band for eight straight quarters. The Q1 2026 operating income of $2.586 billion on $6.96 billion of revenue reflects disciplined cost control, with R&D of $1.372 billion (19.7% of revenue) and SG&A of $1.451 billion (20.8% of revenue), and the 39.74% operating margin is well above the typical large-cap pharma range of roughly 25-30%, reflecting the high-margin antiviral mix. The key watch item is that the aggressive acquisition program (Arcellx, Tubulis, Ouro) will add amortization and integration costs that could pressure reported margins even as it builds the long-term pipeline. The balance sheet and cash generation are healthy but leveraged. Debt-to-equity stands at 1.098, the current ratio is 1.553, and TTM free cash flow is $10.229 billion, which against a market cap of roughly $152.7 billion implies an FCF yield of about 6.7%, a strong cash return for a large-cap pharma. Q1 2026 operating cash flow was $2.544 billion with free cash flow of $2.427 billion, comfortably covering the $1.04 billion of dividends paid and $419 million of buybacks in the quarter, and ROE of 37.49% and ROA of 14.09% are excellent, though the Q1 2026 debt repayment of $2.766 billion shows management is actively deleveraging. The company funds growth internally and returns cash to shareholders, but the serial M&A strategy means external capital deployment remains a core part of the story, and the 47.04% payout ratio leaves room for the dividend to grow without straining the balance sheet.
Quarterly Revenue
$7.0B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
79.2%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Because Gilead is solidly profitable with positive net income of $2.021 billion in the latest quarter, the PE ratio is the appropriate primary metric. The trailing PE is 17.94x versus a forward PE of 14.53x, and the roughly 19% compression between the two implies the market expects meaningful earnings growth over the next twelve months, consistent with the consensus EPS estimate of $13.09 versus the current trailing EPS of $0.056 (a figure distorted by one-time items and not comparable to the forward estimate). The forward PE of 14.53x on $13.09 of expected EPS is the more economically meaningful anchor, and it frames Gilead as a value-priced large-cap pharma rather than a growth multiple. On a peer basis, Gilead screens cheap. The PS ratio of 5.19x and EV/Sales of 6.59x are moderate for a company with a 79.24% gross margin and a 29.04% net margin, and the EV/EBITDA of 12.52x is below the 15-18x range typical of large-cap pharma peers, while the PB ratio of 6.73x is elevated only because of the high ROE and relatively thin book equity. The PEG ratio of 0.011 is anomalously low and reflects a distorted trailing growth denominator rather than a genuine signal, so it should be discounted; the more reliable read is that a 14.5x forward PE for a business with a 6.7% FCF yield and a 2.62% dividend yield represents a discount to the broad healthcare sector, justified by the low-single-digit revenue growth rate and pipeline execution risk rather than by any balance-sheet weakness. Historically, Gilead's own valuation band has been wide. The historical ratios show PE ratios ranging from a low of 10.71x (Q3 2023) to a high of 26.43x (Q1 2025), with the current trailing PE of 17.94x sitting near the middle of that band, and PS ratios ranging from 10.99x (Q3 2022) to 24.87x (Q1 2026), with the current 5.19x PS reading far below the historical range because the historical figures appear to be computed on a different share/revenue basis. The PB ratio of 6.73x is near the high end of its own history (versus 4.19x in Q3 2023 and 5.96x in Q4 2024), which suggests the market is already pricing in a fair amount of optimism about the oncology pipeline and HIV reacceleration, leaving less margin of safety than the absolute PE multiple alone would imply.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Gilead's financial risks are moderate but manageable. The debt-to-equity ratio of 1.098 reflects the company's aggressive acquisition strategy, with recent deals like Arcellx ($7.8 billion) and Tubulis ($3.15 billion) adding leverage. However, TTM free cash flow of $10.23 billion comfortably covers the $1.04 billion in quarterly dividends and $419 million in buybacks, and the current ratio of 1.553 indicates adequate liquidity. The main financial risk is margin pressure from acquisition-related amortization and integration costs, which could compress the current 39.74% operating margin, especially if the oncology pipeline fails to deliver expected returns.
Market and competitive risks are significant given Gilead's premium valuation relative to its growth rate. The forward PE of 14.53x may appear cheap, but the PB ratio of 6.73x is near the high end of its historical range, suggesting the market is already pricing in optimism about the pipeline. The beta of 0.35 means Gilead is less sensitive to market swings, but it also limits upside in a broad rally. Competitive threats include potential pricing pressure in HIV, where Gilead holds a dominant position, and the risk that competitors develop superior therapies. The 100% drug tariff exemption is a current advantage, but it could be rescinded or modified, removing a key competitive moat.
The worst-case scenario for Gilead would be a combination of HIV growth stagnation, further oncology pipeline failures, and multiple compression. If Bixlenvo fails to gain traction and the Arcellx myeloma program disappoints, the stock could retest its 52-week low of $108.46, representing a 24.5% decline from the current price of $143.72. The analyst low target of $123.00 implies a 14.4% downside, but a more severe scenario could see the stock fall to the 52-week low, especially if acquisition-related costs erode margins and free cash flow declines. In this adverse scenario, an investor could lose approximately 25% from the current price, with the possibility of further downside if the HIV franchise faces unexpected competitive or regulatory challenges.
FAQ
The key risks include: 1) HIV concentration risk, as HIV products account for over 72% of revenue, so any pricing pressure or competitive threat could significantly impact financials. 2) Pipeline risk, highlighted by the termination of the Trodelvy-Keytruda lung cancer trial, which raises doubts about the oncology strategy. 3) Financial risk from aggressive M&A, with debt-to-equity at 1.098 and potential margin pressure from acquisition amortization. 4) Macro and regulatory risk, including the possibility that the 100% drug tariff exemption could be revoked, removing a competitive advantage. These risks are ranked from most to least severe, with HIV concentration being the most critical.
The 12-month forecast includes three scenarios: bull case (25% probability) with a target range of $170-180, driven by Bixlenvo success and pipeline progress; base case (55% probability) with a target range of $150-165, assuming steady HIV growth and modest oncology contribution; and bear case (20% probability) with a target range of $108-123, if Bixlenvo disappoints and pipeline failures continue. The base case is most likely, supported by the analyst average target of $158.15. The key assumption is that HIV revenue grows 4-5% annually and no major new setbacks occur.
Gilead appears fairly valued to slightly undervalued. Its forward PE of 14.53x is below the 15-18x range typical for large-cap pharma peers, and its EV/EBITDA of 12.52x is also at a discount. The PS ratio of 5.19x and EV/Sales of 6.59x are moderate for a company with a 79.24% gross margin. However, the PB ratio of 6.73x is near the high end of its historical range, suggesting the market is pricing in optimism about the pipeline. Compared to its own historical PE band of 10.71x to 26.43x, the current 17.94x trailing PE is near the middle. The valuation implies the market expects modest growth, and any acceleration could lead to multiple expansion.
Gilead offers a compelling risk/reward for value-oriented investors, with a forward PE of 14.53x, a 6.7% free cash flow yield, and a 2.62% dividend yield. The analyst consensus is 'buy' with an average target of $158.15, implying about 10% upside. However, the stock faces risks including low revenue growth of 4.39%, pipeline setbacks like the Trodelvy trial failure, and integration risk from recent acquisitions. It is a good buy for conservative investors seeking income and low volatility (beta 0.35), but less suitable for those seeking high growth. The biggest downside risk is a retest of the 52-week low of $108.46, representing a 24.5% decline.
Gilead is better suited for long-term investment, given its low beta of 0.35, stable dividend yield of 2.62%, and strong free cash flow generation. The company is in a mature growth stage, with revenue growing at 4.39% and a focus on returning cash to shareholders through dividends and buybacks. Short-term trading is less attractive due to the stock's low volatility and range-bound technical pattern. A minimum holding period of 2-3 years is recommended to allow for the Bixlenvo launch and oncology pipeline to mature, and to benefit from potential multiple expansion. The dividend and buybacks provide a floor for total returns.
